Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akzo Nobel

This article was originally published in The Gray Sheet

Executive Summary

Dutch conglomerate completes divestiture of the in vitro diagnostics business of its Organon Teknika unit to bioMerieux for about $260 mil. Initially proposed in February, the move will expand bioMerieux' diagnostics revenues to about $1 bil. and allow Organon to focus on its core pharmaceuticals business (1"The Gray Sheet" Feb. 19, 2001, p. 14)
Advertisement

Related Content

BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
Advertisement
UsernamePublicRestriction

Register

MT015106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel